Sun Pharma share price jumps after Q4 results; should you buy or sell stock?

By: |
May 29, 2019 2:54 PM

Shares of India's major drug-maker Sun Pharma surged in trade on Wednesday, after the firm reported Q4 results. We take a look at what brokerages have to say.

sun pharma, sun pharma result, sun pharma market result, sun pharma dividend, sun pharma indutries, सन फॉर्माSun Pharma shares gained more than 2.8% to hit the day’s high at Rs 424.55.

Shares of India’s major drug-maker Sun Pharma surged in trade on Wednesday, after the firm reported Q4 results. Sun Pharma shares gained more than 2.8% to hit the day’s high at Rs 424.55. In the latest quarter, Sun Pharma has reported a 53% drop in profit to Rs 635.90 crore, after the firm took a Rs 1,085 crore one-time charge on account of restructuring of distribution business (transferred to subsidiary from Aditya Medisales). Sun Pharma had reported a net profit of  Rs 1,342 crore in the comparable quarter last year, India’s largest drug maker said in a stock exchange filing on Tuesday.

Also read: Modi’s return could boost these small-midcap stocks, Nifty may be headed for 13,500: Kotak Securities

Taking stock of the reported results, global brokerage firm Nomura said that it has a buy rating on the stock with a target price of Rs 536. “The adjusted Q4 sales were 2.5% below our estimate and FY20 guidance was below our current estimates,” noted the firm. Further, EBITDA in Q4 was supported by one-time generic sales opportunity and US revenues positively impacted by one-time generic revenue opportunity, said the report.

Sharing its take on Sun Pharma’s performance in the quarter, Reliance Securities said that it was a decent show as there was an improvement in the US business; and distribution transition in domestic business is on track. “Recently, Sun Pharma has addressed some corporate governance issues raised by the investors, which in our view is a very positive move. We view SEBI-related issues as event-specific risks for the stock in the near-term,” Reliance Securities said. The research firm noted that the current valuation (PE multiple of 16.6x FY21E earnings) offers favourable risk-reward, and accordingly maintained a buy recommendation on the stock with a revised target price of Rs 500 (from Rs535 earlier).

According to Jefferies, the fourth quarter was a weak one led by investment in Ilumya and FY20 guidance is mixed. FY20 topline target is in-line but guidance for R&D & promotional spend is higher, said the firm. “With valuations at 20% discount to 16x FY21 PE, we have a buy call on the stock but have slashed price target to Rs 520 from Rs 540 as EPS estimated for FY20/21 has been cut by 10/3 percent,” said the firm.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1TCS leads 8 of 10 most-valued firms to add Rs 81,250.83 cr in market valuation last week
2Earnings, COVID-19 updates, macro data to guide market sentiment: Analysts
3Best blue chip stocks to buy for long-term; check how to track multibagger stocks